Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

Clinical trial NCT02496663 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02496663
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Metastatic Lung Non-Small Cell Carcinoma Recurrent Lung Non-Small Cell Carcinoma Stage IV Lung Cancer AJCC v8

Start date: 2016-05-11
Primary completion: 2027-06-30
Enrollment: 138

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.